Swiss biopharmaceutical company Debiopharm has entered into a strategic research collaboration with South Korea–based biotech firm NetTargets to accelerate the discovery of novel, synergistic drug combinations for next-generation Antibody-Drug Conjugates (ADCs). The partnership brings together NetTargets’ AI-powered discovery platform with Debiopharm’s proprietary MLINK Duo technology to design dual-payload ADCs aimed at overcoming treatment resistance in cancer.
The collaboration integrates NetTargets’ advanced artificial intelligence systems, which analyze multi-omics data to uncover potent synergistic drug pairings, with Debiopharm’s MLINK Duo linker technology, capable of carrying and delivering two distinct payloads on a single antibody. This combination enables precise delivery of both therapeutic agents directly into cancer cells, maximizing efficacy while minimizing toxicity.
“To address the fundamental challenge of therapeutic resistance, we are moving beyond single-agent attacks,” said Frédéric Lévy, Chief Scientific Officer at Debiopharm. “By combining AI-driven discovery with our ADC expertise, we can rationally design more effective and durable cancer therapies.”
Debiopharm’s MLINK Duo platform is part of the company’s broader effort to develop bispecific ADCs and innovative payloads, leveraging its clinical development experience to deliver next-generation cancer treatments more efficiently.
Dr. Je-Hoon Song, CEO of NetTargets, added, “Our AI models can simulate complex biological interactions to identify unique vulnerabilities in tumors. Partnering with Debiopharm allows us to turn these digital insights into real-world cancer therapies.”
Through this collaboration, Debiopharm and NetTargets aim to pioneer a new class of dual-action ADCs, setting the stage for smarter, more precise, and more resilient oncology treatments.